牛牛AI助手已提取核心信息
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
2024年2月27日，处于临床阶段的制药公司ScisPARC Ltd. 宣布与Clearmind Medicine Inc. 合作提交了三项新的国际专利申请。这些根据《专利合作条约》（PCT）提交的申请涵盖了****、伊博加因和****的新成分，每种成分都与棕榈酰乙醇胺（PEA）（ScisPARC的CannaMide™ 中的一种活性成分）结合在一起。这些专利旨在开发中枢神经系统疾病和罕见疾病的疗法。以前，这些化合物的临时专利是向美国专利商标局（USPTO）申请的。此外，Clearmind还提交了另外八份美国专利商标局申请和七份不同组合的PCT申请，包括酒精使用障碍、可卡因成瘾和肥胖相关代谢障碍的治疗。ScisPARC专门研究基于大麻素的药物，目前正在研究针对图雷特综合症、阿尔茨海默氏病、疼痛、自闭症障碍和癫痫持续状态等疾病的药物开发项目。
2024年2月27日，处于临床阶段的制药公司ScisPARC Ltd. 宣布与Clearmind Medicine Inc. 合作提交了三项新的国际专利申请。这些根据《专利合作条约》（PCT）提交的申请涵盖了****、伊博加因和****的新成分，每种成分都与棕榈酰乙醇胺（PEA）（ScisPARC的CannaMide™ 中的一种活性成分）结合在一起。这些专利旨在开发中枢神经系统疾病和罕见疾病的疗法。以前，这些化合物的临时专利是向美国专利商标局（USPTO）申请的。此外，Clearmind还提交了另外八份美国专利商标局申请和七份不同组合的PCT申请，包括酒精使用障碍、可卡因成瘾和肥胖相关代谢障碍的治疗。ScisPARC专门研究基于大麻素的药物，目前正在研究针对图雷特综合症、阿尔茨海默氏病、疼痛、自闭症障碍和癫痫持续状态等疾病的药物开发项目。
有用
没用